BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 23133955)

  • 1. [Molecularly target therapy].
    Kiyoi H
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():211-6. PubMed ID: 23133955
    [No Abstract]   [Full Text] [Related]  

  • 2. [New agents for solid tumours].
    Raida M
    Dtsch Med Wochenschr; 2006 Oct; 131(43):2407-10. PubMed ID: 17054057
    [No Abstract]   [Full Text] [Related]  

  • 3. Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.
    Zhu N; Xiao H; Wang LM; Fu S; Zhao C; Huang H
    Future Oncol; 2015; 11(4):659-73. PubMed ID: 25686120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.
    Chase A; Cross NC
    Clin Sci (Lond); 2006 Oct; 111(4):233-49. PubMed ID: 16961463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Protein tyrosine kinase inhibitors in cancer therapy].
    Boutayeb S; Zakkouri FZ; Aitelhaj M; Mesmoudi M; Boutayeb A; Boutayeb W; Mrabti H; Errihani H
    Pathol Biol (Paris); 2012 Aug; 60(4):229-33. PubMed ID: 22743095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hematologic malignancies /pediatric malignancies-current status of molecular target therapy for hematologic cancer].
    Usui N
    Gan To Kagaku Ryoho; 2010 May; 37(5):805. PubMed ID: 20524247
    [No Abstract]   [Full Text] [Related]  

  • 7. [Hematologic malignancies/pediatric malignancies].
    Usui N
    Gan To Kagaku Ryoho; 2012 May; 39(5):731. PubMed ID: 22701898
    [No Abstract]   [Full Text] [Related]  

  • 8. [Limitations in application of imatinib in hematologic malignancies: are there new principal solutions?].
    Rukavitsyn OA; Pop VP
    Ter Arkh; 2008; 80(7):80-4. PubMed ID: 18763606
    [No Abstract]   [Full Text] [Related]  

  • 9. Signal transduction inhibitors (STI571): molecularly targeted therapy.
    Corujo Y; Cáceres W
    P R Health Sci J; 2002 Sep; 21(3):203-5. PubMed ID: 12243110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EPHA3 as a novel therapeutic target in the hematological malignancies.
    Keane N; Freeman C; Swords R; Giles FJ
    Expert Rev Hematol; 2012 Jun; 5(3):325-40. PubMed ID: 22780212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A role of new molecular-target drugs for hematologic malignancies].
    Usui N
    Gan To Kagaku Ryoho; 2015 May; 42(5):548-9. PubMed ID: 26054087
    [No Abstract]   [Full Text] [Related]  

  • 12. [Trends in development of molecular targeted therapy for hematological neoplasms].
    Nagai T
    Rinsho Ketsueki; 2012 Oct; 53(10):1768-75. PubMed ID: 23037750
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
    Heinrich MC; Joensuu H; Demetri GD; Corless CL; Apperley J; Fletcher JA; Soulieres D; Dirnhofer S; Harlow A; Town A; McKinley A; Supple SG; Seymour J; Di Scala L; van Oosterom A; Herrmann R; Nikolova Z; McArthur AG;
    Clin Cancer Res; 2008 May; 14(9):2717-25. PubMed ID: 18451237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Targeted therapy in hematologic neoplasia: overview].
    Tauchi T; Ohyashiki K
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():395-8. PubMed ID: 17474436
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel targeted agents for the treatment of advanced breast cancer.
    de la Vega M; Díaz-Cantón E; Alvarez RH
    Future Med Chem; 2012 May; 4(7):893-914. PubMed ID: 22571614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [mTOR complexes -- molecular spiders in molecular networks].
    Kopper L; Tímár J
    Magy Onkol; 2011 Nov; 55(4):287-94. PubMed ID: 22128312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies.
    Ravandi F; Talpaz M; Estrov Z
    Clin Cancer Res; 2003 Feb; 9(2):535-50. PubMed ID: 12576416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging targets for hematological malignancies.
    Cilloni D; Frassoni F; Saglio G
    Curr Opin Drug Discov Devel; 2010 Sep; 13(5):548-58. PubMed ID: 20812146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signal-transduction inhibitors in renal cell carcinoma.
    Vogelzang NJ; Sternberg CN
    BJU Int; 2007 May; 99(5 Pt B):1289-95. PubMed ID: 17441926
    [No Abstract]   [Full Text] [Related]  

  • 20. [Chemotherapy in elderly patients with hematological malignancies].
    Ohnishi K
    Gan To Kagaku Ryoho; 2011 Oct; 38(10):1586-90. PubMed ID: 21996952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.